BeiGene, Ltd.
51Patents
51Active
51Granted
55Portfolio score
Filing activity: Dec 31, 2011 → Apr 30, 2024
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8735553B1 | Anti-PD1 antibodies and their use as therapeutics and diagnostics | Chemistry; Metallurgy | 261 | Active |
| US9328111B2 | Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitors | Chemistry; Metallurgy | 101 | Active |
| US9834606B2 | Anti-PD1 antibodies and their use as therapeutics and diagnostics | Chemistry; Metallurgy | 45 | Active |
| US9217034B2 | Anti-PD1 antibodies and their use as therapeutics and diagnostics | Chemistry; Metallurgy | 36 | Active |
| US9447106B2 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | Chemistry; Metallurgy | 24 | Active |
| US9556188B2 | Substituted imidazo[1,2-b]pyrazoles as bruton'S tyrosine kinase modulators | Chemistry; Metallurgy | 24 | Active |
| US10005782B2 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | Chemistry; Metallurgy | 23 | Active |
| US9393232B2 | Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones | Emerging Cross-Sectional Technologies | 16 | Active |
| US10544225B2 | Anti-PD-L1 antibodies and their use as therapeutics and diagnostics | Chemistry; Metallurgy | 15 | Active |
| US11512132B2 | Anti-PD-L1 antibodies and their use as therapeutics and diagnostics | Chemistry; Metallurgy | 10 | Active |
| US10864203B2 | Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer | Chemistry; Metallurgy | 8 | Active |
| US11555038B2 | Crystalline forms of (S)-7-(1-(but-2-ynoyl)piperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | Chemistry; Metallurgy | 7 | Active |
| US11202782B2 | Treatment cancers using a combination comprising PARP inhibitors | Chemistry; Metallurgy | 6 | Active |
| US11597768B2 | Immunotherapy for hepatocellular carcinoma | Chemistry; Metallurgy | 6 | Active |
| US11203637B2 | Anti-Tim-3 antibodies and use thereof | Emerging Cross-Sectional Technologies | 6 | Active |
| US9273046B2 | Fused tricyclic compounds as Raf kinase inhibitors | Chemistry; Metallurgy | 6 | Active |
| US9260440B2 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors | Chemistry; Metallurgy | 5 | Active |
| US9617273B2 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors | Chemistry; Metallurgy | 5 | Active |
| US9670231B2 | Fused tricyclic amide compounds as multiple kinase inhibitors | Chemistry; Metallurgy | 5 | Active |
| US10280163B2 | 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases | Human Necessities | 4 | Active |
| US10112952B2 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors | Chemistry; Metallurgy | 4 | Active |
| US11377449B2 | BTK inhibitors with improved dual selectivity | Chemistry; Metallurgy | 3 | Active |
| US9670203B2 | Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors | Emerging Cross-Sectional Technologies | 3 | Active |
| US9895376B2 | Fused tricyclic compounds as Raf kinase inhibitors | Chemistry; Metallurgy | 3 | Active |
| US10647714B2 | 5 or 8-substituted imidazo[1,5-a]pyridines as indoleamine and/or tryptophane 2,3-dioxygenases | Human Necessities | 2 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.